Blog hero image

Blog

Kidney Cancer Highlights from 2026 ASCO GU thumbnail image

Kidney Cancer Highlights from 2026 ASCO GU

Mar . 09 . 2026
Research
We rounded up a few research highlights from the 2026 ASCO Genitourinary Cancers Symposium (ASCO GU), held recently in San Francisco, California. Altitude can affect oxygen-related side effects from belzutifan The approval of the hypoxia-inducible factor (HIF-2a) belzutifan by the FDA offered a new treatment option for kidney cancer patients that harnessed the cellular mechanism by which cells can adapt to environments…
Read More
2026 ASCO GU: Two Positive Trials for Belzutifan Combination Therapy thumbnail image

2026 ASCO GU: Two Positive Trials for Belzutifan Combination Therapy

Mar . 09 . 2026
Research
This is a research highlight from the 2026 ASCO Genitourinary Cancers Symposium (ASCO GU), held recently in San Francisco, California. Belzutifan (Welireg, made by Merck), the most recently approved kidney cancer drug (2021 and 2023) that uses a new biological method to treat disease, has progressed to clinical trials using it in combination with existing immunotherapy and targeted therapies at different times…
Read More